1. Home
  2. SYBX vs HUBC Comparison

SYBX vs HUBC Comparison

Compare SYBX & HUBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • HUBC
  • Stock Information
  • Founded
  • SYBX N/A
  • HUBC 2017
  • Country
  • SYBX United States
  • HUBC Israel
  • Employees
  • SYBX N/A
  • HUBC N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • HUBC
  • Sector
  • SYBX Health Care
  • HUBC
  • Exchange
  • SYBX Nasdaq
  • HUBC Nasdaq
  • Market Cap
  • SYBX 16.5M
  • HUBC 15.2M
  • IPO Year
  • SYBX N/A
  • HUBC N/A
  • Fundamental
  • Price
  • SYBX $1.36
  • HUBC $0.71
  • Analyst Decision
  • SYBX Hold
  • HUBC
  • Analyst Count
  • SYBX 1
  • HUBC 0
  • Target Price
  • SYBX N/A
  • HUBC N/A
  • AVG Volume (30 Days)
  • SYBX 19.0K
  • HUBC 3.2M
  • Earning Date
  • SYBX 03-18-2025
  • HUBC 12-13-2024
  • Dividend Yield
  • SYBX N/A
  • HUBC N/A
  • EPS Growth
  • SYBX N/A
  • HUBC N/A
  • EPS
  • SYBX N/A
  • HUBC N/A
  • Revenue
  • SYBX $2,777,000.00
  • HUBC $33,357,000.00
  • Revenue This Year
  • SYBX N/A
  • HUBC N/A
  • Revenue Next Year
  • SYBX N/A
  • HUBC N/A
  • P/E Ratio
  • SYBX N/A
  • HUBC N/A
  • Revenue Growth
  • SYBX 292.23
  • HUBC N/A
  • 52 Week Low
  • SYBX $1.22
  • HUBC $0.37
  • 52 Week High
  • SYBX $2.04
  • HUBC $2.17
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 45.23
  • HUBC 44.40
  • Support Level
  • SYBX $1.31
  • HUBC $0.64
  • Resistance Level
  • SYBX $1.40
  • HUBC $0.88
  • Average True Range (ATR)
  • SYBX 0.07
  • HUBC 0.20
  • MACD
  • SYBX 0.00
  • HUBC -0.04
  • Stochastic Oscillator
  • SYBX 60.61
  • HUBC 8.55

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About HUBC Hub Cyber Security Ltd.

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

Share on Social Networks: